Mission

Our mission is to uncover and advance the therapeutic and diagnostic potential of the remarkable PreImplantation Factor (PIF) molecule. Guided by a deep sense of purpose, we are committed to translating its natural design into innovative solutions that enhance human health and improve lives.

Vision

We believe in the extraordinary potential of a naturally occurring molecule—one that initiates and sustains human pregnancy, fosters fetal development, and protects life before birth. We envision PIF extending its purpose beyond pregnancy to offer powerful health benefits for all people, supporting healing, survival, and a higher quality of life.

History

Prince Biotech is a research-driven organization with a mission to understand the unique immune environment of pregnancy—an altered state that allows the maternal body to support and protect a developing fetus. This curiosity led to groundbreaking insights into the molecular mechanisms behind immune tolerance and regeneration, particularly the role of PreImplantation Factor (PIF).

Prince Biotech and its subsidiaries have built a distinguished global network of collaborators, published over 50 peer-reviewed scientific studies, developed a robust patent portfolio, and successfully completed a Phase I FDA toxicology/safety study that, together, have laid the foundation for our evolution into a clinical-stage biotechnology company.

Today, we are focused on developing immuno- and regenerative therapeutics that meet clear clinical and commercial needs. Our programs target conditions with high unmet medical demand and strong scientific rationale, including those supported by U.S. government grants and several FDA Orphan Drug Designations—such as acute radiation syndrome, traumatic brain injury, and stroke. Prince Biotech continues to advance innovative therapies that have the potential to transform patient care.